Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease by Cyrus Huneycutt | Dec 3, 2025 | 0 comments Submit a Comment Cancel replyYou must be logged in to post a comment.
Recent Comments